A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Agnostos Trial is a multicentric phase 2 randomized trial with a 'pick-the-winner design' in
chemonaive patients with cancer of unknown primary. It will assess the efficacy of the two
best active single agent - carboplatin or gemcitabine - added to an innovative taxane back
bone (nab-Paclitaxel). Agnostos trial is a part of a larger clinical and translational
initiative to improve the outlook of patients with cancer of unknown primary through
evaluation of novel chemotherapeutic regimens.